CL2007002667A1 - Uso de trastuzumab para la prevencion o reduccion de la metastasis en un paciente que padece de cancer her2 positivo, que no responde a una monoterapia con trastuzumab ni a una monoterapia con pertuzumab. - Google Patents

Uso de trastuzumab para la prevencion o reduccion de la metastasis en un paciente que padece de cancer her2 positivo, que no responde a una monoterapia con trastuzumab ni a una monoterapia con pertuzumab.

Info

Publication number
CL2007002667A1
CL2007002667A1 CL2007002667A CL2007002667A CL2007002667A1 CL 2007002667 A1 CL2007002667 A1 CL 2007002667A1 CL 2007002667 A CL2007002667 A CL 2007002667A CL 2007002667 A CL2007002667 A CL 2007002667A CL 2007002667 A1 CL2007002667 A1 CL 2007002667A1
Authority
CL
Chile
Prior art keywords
monotherapy
trastuzumab
pertuzumab
metastasis
respond
Prior art date
Application number
CL2007002667A
Other languages
English (en)
Inventor
Thomas Friess
Max Hasmann
Werner Scheuer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38608749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007002667(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2007002667A1 publication Critical patent/CL2007002667A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de trastuzumab para la prevención o reducción de la metástasis en un paciente que padece de cáncer her2 positivo, que no responde a una monoterapia con trastuzumab ni a una monoterapia con pertuzumab.
CL2007002667A 2006-09-15 2007-09-13 Uso de trastuzumab para la prevencion o reduccion de la metastasis en un paciente que padece de cancer her2 positivo, que no responde a una monoterapia con trastuzumab ni a una monoterapia con pertuzumab. CL2007002667A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06019317 2006-09-15
EP07006616 2007-03-30

Publications (1)

Publication Number Publication Date
CL2007002667A1 true CL2007002667A1 (es) 2008-01-25

Family

ID=38608749

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2007002667A CL2007002667A1 (es) 2006-09-15 2007-09-13 Uso de trastuzumab para la prevencion o reduccion de la metastasis en un paciente que padece de cancer her2 positivo, que no responde a una monoterapia con trastuzumab ni a una monoterapia con pertuzumab.

Country Status (6)

Country Link
US (1) US20080102069A1 (es)
AR (1) AR062840A1 (es)
CL (1) CL2007002667A1 (es)
PE (1) PE20080663A1 (es)
TW (1) TW200820987A (es)
WO (1) WO2008031531A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089566A1 (en) 2000-05-19 2001-11-29 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
UA90480C2 (uk) * 2004-07-22 2010-05-11 Джэнэнтэк, Инк. Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
RS53128B (sr) 2005-02-23 2014-06-30 Genentech Inc. Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US8012914B2 (en) 2006-10-27 2011-09-06 Halliburton Energy Services, Inc. Ortho ester breakers for viscoelastic surfactant gels and associated methods
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
TW201010732A (en) * 2008-08-29 2010-03-16 Enzon Pharmaceuticals Inc Method of treating RAS associated cancer
EP2337800B1 (en) 2008-09-15 2013-10-02 Yeda Research and Development Co. Ltd. Antibody combinations and use of same for treating cancer
US20100098654A1 (en) * 2008-10-21 2010-04-22 Fabio Pastorino Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
US8637084B2 (en) * 2009-07-14 2014-01-28 Asahi Kasei Medical Co., Ltd. Treatment method for epithelial cancerous organism
EP2456464A4 (en) * 2009-07-22 2013-02-20 Enzon Pharmaceuticals Inc METHOD FOR THE TREATMENT OF HER2-POSITIVE CANCER WITH HER2 RECEPTOR ANTAGONISTS IN COMBINATION WITH MULTICARM POLYMER CONJUGATES FROM 7-ETHYL-10-HYDROXYCAMPTOTHECIN
US8609095B2 (en) * 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
NZ604007A (en) 2010-05-27 2015-03-27 Genmab As Monoclonal antibodies against her2 epitope
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
WO2012059857A2 (en) * 2010-11-01 2012-05-10 Symphogen A/S Pan-her antibody composition
EP2699260B1 (en) * 2011-04-20 2024-11-20 Genmab A/S Bispecifc antibodies against her2
CA2832387A1 (en) * 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
WO2012143524A2 (en) * 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
US9040047B2 (en) 2011-05-16 2015-05-26 Yeda Research And Development Co. Ltd. Combinations of anti ErbB antibodies for the treatment of cancer
FR2976294B1 (fr) * 2011-06-10 2018-02-16 Universite De Nice Sophia Antipolis Methode de prediction de la reponse a un traitement avec un agent bloquant her2
HUE044352T2 (hu) * 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
WO2013096812A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
HK1202431A1 (en) 2012-05-02 2015-10-02 Symphogen A/S Humanized pan-her antibody compositions
MY173295A (en) 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
KR101453462B1 (ko) 2013-05-16 2014-10-23 앱클론(주) Her2에 특이적으로 결합하는 항체
RU2689145C2 (ru) * 2014-04-16 2019-05-24 Биокон Лтд. Стабильные белковые препараты, содержащие молярный избыток сорбитола
BR112016024789A2 (pt) 2014-04-25 2017-10-24 Genentech Inc métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe
WO2016077739A1 (en) * 2014-11-13 2016-05-19 The Curators Of The University Of Missouri Multiple human antibody-nanoparticle conjugates and methods of formation
FI3223848T3 (fi) * 2014-11-27 2025-02-28 Zymeworks Bc Inc Menetelmiä käyttää bispesifisiä antigeenia sitovia rakenteita, jotka kohdistuvat her2:een
JP6822980B2 (ja) 2015-05-30 2021-01-27 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性転移性乳癌の治療方法
TWI870335B (zh) * 2015-06-12 2025-01-21 美商宏觀基因股份有限公司 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
KR101796277B1 (ko) 2016-04-12 2017-11-13 앱클론(주) 안정성이 개선된 ｈｅｒ２에 특이적으로 결합하는 항체
EP3534948A1 (en) 2016-11-04 2019-09-11 Genentech, Inc. Treatment of her2-positive breast cancer
JP6914336B2 (ja) * 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
DK3570884T3 (da) 2017-01-17 2020-11-30 Genentech Inc Subkutane HER2-antistofformuleringer
HUE064898T2 (hu) 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
AU2019450366B2 (en) * 2019-06-11 2026-01-08 Board Of Regents, The University Of Texas System Use of an RXR agonist in treating Her2+ cancers
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤
AU2021308283A1 (en) * 2020-07-14 2023-02-02 F. Hoffmann-La Roche Ag Assays for fixed dose combinations
KR20240115316A (ko) 2021-12-07 2024-07-25 아이오 테라퓨틱스, 인크. 약물 내성 her2+ 암 치료에서의 rxr 작용제의 용도
EP4444287A4 (en) 2021-12-07 2025-05-28 Io Therapeutics, Inc. USE OF AN RXR AGONIST AND TAXANES FOR THE TREATMENT OF HER2+ CANCER

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR024464A1 (es) * 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.

Also Published As

Publication number Publication date
PE20080663A1 (es) 2008-05-17
WO2008031531A1 (en) 2008-03-20
TW200820987A (en) 2008-05-16
US20080102069A1 (en) 2008-05-01
AR062840A1 (es) 2008-12-10

Similar Documents

Publication Publication Date Title
MX2010006823A (es) Metodos para el tratamiento de la gota.
UA101487C2 (en) Humanized b-ly1 antibody formulation
CA111398S (en) Bottle
CA111399S (en) Bottle
CL2008001498A1 (es) Uso de un anticuerpo contra el factor d en la prevencion o tratamiento de una condicion ocular asociada al complemento.
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
MX2010002406A (es) Terapia de combinacion con anticuerpos anti-cd20 de tipo i y de tipo ii.
ECSP099833A (es) Anticuerpos humanizados contra el globulomero a?(20-42) y sus usos
CY1112288T1 (el) Θεραπεια του καρκινου με αντισωματα κατα της il-1a
WO2009053038A3 (en) Combination therapy of a type ii anti-cd20 antibody with a proteasome inhibitor
TW200605907A (en) Preventing autoimmune disease
CA111400S (en) Bottle
MA33470B1 (fr) Polythérapie à base d'un anticorps afucosylé anti-cd20 et de fludarabine et/ou mitoxantrone
MX2011006725A (es) Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
CA109052S (en) Faucet
EA200970885A1 (ru) Комбинирование лечения рака с применением il-18 человека и антитела против cd20
UA104469C2 (uk) Спосіб запобігання діареї мандрівників
EA200970816A1 (ru) Новая лекарственная форма
EA201000433A1 (ru) Лечение вазомоторных симптомов
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
AU312299S (en) Circular saw
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
CA118181S (en) Shower
UY31995A (es) Uso de idrabiotaparinux para disminuir la incidencia de hemorragias durante un tratamiento antitrombótico
UA96426C2 (ru) Выделенное человеческое или гуманизированное антитело, которое специфически связывается с il-13